Back to Clinical Trials

Brief Title: Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase I Study of Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC), Urothelial Cancer and Advanced Malignant Mesothelioma


  • Org Study ID: IST-65
  • Secondary ID: N/A
  • NCT ID: NCT04173338
  • Sponsor: Augusta University


This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

  • Overall Status
  • Start Date
    January 23, 2020
  • Phase
    Phase 1
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Non Small Cell Lung Cancer
  • Non-squamous Non-small-cell Lung Cancer
  • Urothelial Carcinoma
  • Malignant Mesothelioma


Inclusion Criteria:
* Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.

- * 18 years or older.

- * At least one prior chemotherapy before entering in this trial.

- * Not pregnant or breastfeeding.
Exclusion Criteria:
* Prior treatment with cabozantinib.

- * Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).

- * History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Nagla A Karim, MD, PhD

Role: Principal Investigator

Affiliation: Augusta University Georgia Cancer Center

Overall Contact

Name: N/A

Phone: N/A

Email: N/A


Facility Status Contact